



1Q 2017 PERFORMANCE

FINANCIAL RESULTS

SALES WORLDWIDE¹

+3.2%

ON COMPARABLE OPERATIONAL BASIS*

\$6.3BN

BUSINESS SEGMENT SALES

DIAGNOSTICS



\$1.2BN

NUTRITION



\$1.6BN

MEDICAL DEVICES



\$2.4BN

ESTABLISHED PHARMACEUTICALS



\$950MM

BUSINESS HIGHLIGHTS

Strategic Actions Shape the Company for Continued Long-term Success



ACQUIRED ST. JUDE MEDICAL

ABBOTT NOW HAS LEADERSHIP POSITIONS IN ALL BUSINESSES



Medical Devices & Diagnostics Innovation

NEW U.S. PRODUCTS



Patients with the **Assurity MRI™ pacemaker** and the **Tendril™ MRI pacing lead** will have the ability to undergo full body magnetic resonance imaging (MRI) scans, if required.



Ensite Precision™ cardiac mapping system, which helps physicians more effectively treat patients experiencing arrhythmias in the heart.

NEW FREESTYLE® LIBRE DATA



Real-world data² from **50,000** FreeStyle Libre³ users revealed a higher rate of glucose testing. The data show that higher rates of testing were found to be strongly associated with improved glucose control.

ALINITY™ SYSTEMS



Designed to increase efficiency and provide quality results, four Alinity™ systems were launched internationally for clinical chemistry, immunoassay, blood screening and point of care.**

*Comparable operational results are non-GAAP and include the prior year results for St. Jude Medical, and exclude the impact of exchange and prior and current year results for divested businesses. For full financial data and reconciliation of non-GAAP measures, please see our press release dated April 19, 2017.

**Not yet available in the United States.

¹Reported sales +29.7%

²Data on file. Dunn T, Xu Y, Hayter G; Evidence of a Strong Association Between Frequency of Flash Glucose Monitoring and Glucose Control Measures During Real-World Usage.

³Pending FDA approval. Not available for sale in the United States.

FORWARD-LOOKING STATEMENTS

Some statements in this news release may be forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. Abbott cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those indicated in the forward-looking statements. Economic, competitive, governmental, technological and other factors that may affect Abbott's operations are discussed in Item 1A, "Risk Factors" to our Annual Report on Securities and Exchange Commission Form 10-K for the year ended Dec. 31, 2016, and are incorporated by reference. Abbott undertakes no obligation to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law.